Oxidative stress and Alzheimer disease

American Journal of Clinical Nutrition

Volumn 71, Issue 2, 2000, Pages

  Christen, Yves ^a  

^a IPSEN   (France)

Author keywords

Alzheimer disease; Antioxidants; Free radicals; Humans; Metal; Oxidative stress; amyloid

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ALUMINUM; AMYLOID BETA PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; ASCORBIC ACID; CAROTENOID; CHOLINESTERASE INHIBITOR; COPPER; CYTOCHROME C OXIDASE; DEFEROXAMINE; DONEPEZIL; ESTRADIOL; ESTROGEN; FLAVONOID; FREE RADICAL; GINKGO BILOBA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; IRON CHELATING AGENT; MELATONIN; METAL; MONOAMINE OXIDASE B INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SCAVENGER; SELEGILINE; TACRINE; ZINC;

AGING; ALZHEIMER DISEASE; CONFERENCE PAPER; DIET THERAPY; DNA DAMAGE; HUMAN; LIPID PEROXIDATION; MITOCHONDRION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN GLYCOSYLATION; PROTEIN METABOLISM;

GINKGO BILOBA; LETHRINIDAE;

EID: 0033954991     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/71.2.621s     Document Type: Conference Paper

References (117)

1. Younkin SM, Tanzi RE, Christen Y, eds. Presenilins and Alzheimer's disease. Heidelberg, Germany: Springer-Verlag, 1998.
2. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease. Nature 1997;389:603-6.
3. Patterson P, Kordon C, Christen Y, eds. Neuro-immune interactions and neurological and psychiatric disorders. Heidelberg, Germany: Springer-Verlag, 1999.
4. Hartman D. Free radical theory of aging: Alzheimer's disease pathogenesis. Age 1995;18:97-119.
5. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Oxford, United Kingdom: Oxford University Press, 1989.
6. Packer L, Prilipko L, Christen Y, eds. Free radicals in the brain. Heidelberg, Germany: Springer-Verlag, 1992.
7. Ames B, Shingenaga M, Park EM. Oxidation damage and repair: chemical, biological and medical aspects. Elmsford, United Kingdom: Pergamon Press, 1991.
8. Cooper AJL. Glutathione in the brain: disorders of glutathione metabolism. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Klunk LM, eds. The molecular and genetic basis of neurological disease. Boston: Butterworth-Heinemann, 1997:1242-5.
9. Hazel JR, Williams EE. The role of alterations in membrane lipid composition in enabling physiological adaptation of organisms to their physical environment. Prog Lipid Res 1990;29:167-227.
10. Smith MA, Rudnicka-Nawrot M, Richey PL, et al. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 1995;64:2660-6.
11. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 1995;16:661-74.
12. Beal MF, Howell N, Bodis-Wollner IB, eds. Mitochondria and free radicals in neurodegenerative diseases. New York: Wiley-Liss, 1997.
13. Loeffler DA, Connor JR, Juneau PL, et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995;65:710-6.
14. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-47.
15. Smith MA, Richey Harris PL, Sayre L, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997;94:9866-8.
16. Kennard ML, Feldman H, Yamada T, Jefferies WA. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med 1996;2:1230-5.
17. Crapper DR, Quittkat S, Krishnan SS, Dalton AJ, DeBoni U. Intranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy, and experimental aluminum encephalopathy. Acta Neuropathol (Berl) 1980;50:19-24.
18. Bjertness E, Candy JM, Torvik A, et al. Content of brain aluminum is not elevated in Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:171-4.
19. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper (II) to copper (I). Science 1996;271:1406-9.
20. Multhaup G. Amyloid precursor protein, copper and Alzheimer's disease. Biomed Pharmacother 1997;51:105-11.
21. Multhaup G, Masters CL, Beyreuther K. Oxidative stress in Alzheimer's disease. Alzheimer Rep 1998;1:147-54.
22. Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 1996;63(suppl):797S-811S.
23. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 1997;143:137-42.
24. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 1994;265:1464-7.
25. Choi DW, Koh JY. Zinc and brain injury. Annu Rev Neurosci 1998;21:347-75.
26. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-51.
27. Hensey K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146-56.
28. Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994;645:338-42.
29. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and andoxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995;45:1594-601.
30. Marcus DL, Thomas C, Rodriguez C, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease Exp Neurol 1998;150:40-4.
31. Hayn M, Kremser K, Singewald N, et al. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. Life Sci 1996;59:537-44.
32. Lyras L, Cairns NJ, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids and DNA in the brain from patients with Alzheimer's disease. J Neurochem 1997;68:2061-9.
33. Ramassamy C, Krzywokowski P, Bastianetto S, et al. Apolipoprotein E, oxidative stress and EGb 761 in Alzheimer's disease brain. In: Packer L, Christen Y, eds. Ginkgo biloba extract (EGb 761) study: lesson from cell biology. Paris: Elsevier, 1998:69-83.
34. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994;91:7787-91.
35. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149:21-8.
36. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-7.
37. Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-1.
38. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994;91:5710-4.
39. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992;140:621-8.
40. Smith MA, Kutty RK, Richey PL, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994;145:42-7.
41. Schipper HM, Cissé S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 1995; 37:758-68.
42. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995;378:776-9.
43. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 1992;89:1671-5.
44. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998;19:33-6.
45. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 1997;68:255-64.
46. Mattson MP. Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid β-peptide? Neurobiol Aging 1995; 16:679-82.
47. Dugan LL, Sensi SL, Canzoniero LMT, et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci 1995;15:6377-88.
48. Reynolds IJ, Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci 1995;15:3318-27.
49. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J Neurosci 1996;16:2463-78.
50. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998;44:410-3.
51. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994;91:4766-70.
52. Harrington CR, Colaco CALS. A glycation connection. Nature 1994;370:247-8.
53. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995;18:172-6.
54. Mattson MP, Carney JW, Butterfield DA. A tombstone in Alzheimer's? Nature 1995;373:481.
55. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91.
56. Yan SD, Zhu H, Fu J, et al. Amyloid-β peptide-receptor for advanced glycation end product interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 1997;94:5296-301.
57. Goodman Y, Mattson MP. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid β-peptide toxicity. J Neurochem 1996;66:869-72.
58. Mattson MP, Furukawa K, Brace AJ, Mark RJ, Blanc EM. Amyloid cytotoxicity and Alzheimer's disease: roles of membrane oxidation and perturbed ion homeostasis. In: Brioni JD, Decker MW, eds. Pharmacological treatment of Alzheimer's disease: molecular and neurobiological foundations. New York: Wiley, 1997:239-85.
59. Barger SW, Mao X, Moerman AM, Ranganathan A. Mechanistic and metaphorical connections between NF-KB and the secreted Alzheimer's β-amyloid precursor protein. In: Patterson P, Kordon C, Christen Y, eds. Neuro-immune interactions and neurological and psychiatric disorders. Heidelberg, Germany: Springer-Verlag, 1999:57-72.
60. Lezoualc'h F, Behl C. Transcription factor NF-KB: friend or foe of neurons? Mol Psychol 1998;3:15-20.
61. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 1992;86:944-52.
62. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994;77:817-27.
63. Sagara Y, Dargusch R, Klier FG, Schubert D, Behl C. Increased antioxidant enzyme activity in amyloid β protein-resistant cells. J Neurosci 1996;16:497-505.
64. Schubert D, Behl C, Lesley R, et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A 1995; 92:1989-93.
65. Bastianetto S, Ramassamy C, Christen Y, Poirier J, Quirion R. Ginkgo biloba extract (EGb 761) prevents cell death induced by oxidative stress in hippocampal neuronal cell cultures. In: Packer L, Christen Y, eds. Ginkgo biloba extract (EGb 761) study: lesson from cell biology. Advances in EGb 761 research. Vol 7. Paris: Elsevier, 1998:85-99.
66. Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997;17:1683-90.
67. Bruce AJ, Malfroy B, Baudry M. β-amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci U S A 1996; 93:2312-6.
68. Bastianetto S, Ramassamy C, Christen Y, Poirier J, Quirion E. Ginkgo biloba extract (EGb 761) protects in vitro rat hippocampal cells against toxicity induced by β-amyloid peptides. Soc Neurosci 1998;24:1456.
69. Dyrks T, Dyrks E, Harmann R, Masters C, Beyreuther K. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 1992;267:18210-7.
70. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996;380:168-71.
71. Hensley K, Carney J, Mattson M, et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Sci USA 1994;91:3270-4.
72. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J. β-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun 1994;200:710-5.
73. McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 1997;17:2284-94.
74. Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by β-amyloid protein and interferon gamma. Nature 1995; 374:647-50.
75. + accumulation. Proc Natl Acad Sci U S A 1995;92:9328-32.
76. Behl C, Sagara Y. Mechanism of amyloid beta protein induced neuronal cell death: current concepts and future perspectives. J Neural Transm Suppl 1997;49:125-34.
77. Lezoualc'h F, Sagara Y, Holsboer F, Behl C. High constitutive NF-KB activity mediates resistance to oxidative stress in neuronal cells. J Neurosci 1998;18:3224-32.
78. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-KB activation. Science 1996;274:1383-5.
79. Lipton SA. Janus faces of NF-KB: neurodestruction versus neuroprotection. Nat Med 1997;3:20-2.
80. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17:525-30.
81. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet 1996;14:55-61.
82. Leininger-Muller B, Jolivalt C, Bertrand P, Siest G. Oxidation of human apolipoprotein E: isoforms susceptibility and protection with Ginkgo biloba EGb 761 extract. In: Packer L, Christen Y, eds. Ginkgo biloba extract (EGb 761) study: lessons from cell biology. Paris: Elsevier, 1998:57-68.
83. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-66.
84. Mutisaya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994; 63:2179-84.
85. Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 1993;52:580-5.
86. Chandrasekaran K, Giordano T, Brady DR, Stoll J, Martin JL, Rapoport SI. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer's disease. Mol Brain Res 1994;24:336-40.
87. Parker WD, Parks JK. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 1995;45:482-6.
88. Lakis J, Glasco S, Miller SW, Thai LJ, Davis RE. Production of reactive oxygen species correlates with decreased cytochrome oxidase activity in Alzheimer's disease cybrids. Soc Neurosci 1995;21:979.
89. Beal MF. Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 1996;6:661-6.
90. Swerdlow RH, Parks JK, Cassarino DS, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997;49:918-25.
91. Askanas V, McFerrin J, Baqué S, Alvarez RB, Sarkozi E, Engel WK. Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A 1996;93:1314-9.
92. Davis RE, Miller S, Herrnstadt C, et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1997;94:4526-31.
93. Hirano M, Shtilbans A, Mayeux R, et al. Apparent mtDNA heteroplasmy in Alzheimer's disease patients and in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes. Proc Natl Acad Sci U S A 1997;94:14894-9.
94. Wallace DC, Stugard C, Murdock D, Schurr T, Brown MD. Ancient mtDNA sequences in the human nuclear genome: a potential source of errors in identifying pathogenic mutations. Proc Natl Acad Sci U S A 1997;94:14900-5.
95. Davis RE, Miller S, Herrnstadt C, et al. Retraction. Proc Natl Acad Sci U S A 1998;95:12069.
96. Blass JP. Cerebral metabolic impairments. In: Khachaturian ZS, Radebaugh TS, eds. Alzheimer's disease. Cause(s), diagnosis, treatment and care. Boca Raton, FL: CRC Press, 1996:187-205.
97. Shoffner JM. Oxidative phosphorylation defects and Alzheimer's disease. Neurogenetics 1997;1:13-9.
98. Sheu KF, Cooper AJL, Koike K, Koike M, Lindsay JG, Blass JP. Abnormality of the α-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease. Ann Neurol 1994;35:312-8.
99. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: critical review. Cerebrovasc Brain Metab Rev 1991;3;296-335.
100. Pietrini P, Dani A, Furey M, et al. Brain stimulation reverses metabolic reductions in Alzheimer disease. Biol Psychiatry 1996;39:660.
101. Rapoport SI, Hâtanpää K, Brady DR, Chandrasekaran K. Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer's disease. Neurodegeneration 1996;5:473-6.
102. Rapoport SI. Deux stades, réversible et irréversible, de l'insuffisance fonctionnelle dans le cerveau alzheimerien. (Two stages, reversible and irreversible of functional insufficiency in the Alzheimer brain.) In: Besson JM, Bassant MH, Calvino B, et al, eds. De la neurophysiologie à la maladie d'Alzheimer. (The neurophysiology of Alzheimer disease.) Marseille, France: Solal, 1997:165-72 (in French).
103. Crapper McLachlan DR, Dalton AJ, Kruck TPA, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-8.
104. Sano M, Ernesto C. Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
105. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R. Proofs of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
106. Le Bars PL, Katz MM, Berman N, Itil T, Freedman AM, Schalzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-32.
107. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55: 1409-15.
108. DeFeudis F. Ginkgo biloba extract (EGb 761). From chemistry to the clinic. Wiesbaden, Germany: Ullstein-Mosby, 1998.
109. Cohen-Salmon C, Venault P, Martin B, et al. Effects of Ginkgo biloba extract (EGb 761) on learning and possible actions on aging. J Physiol (Paris) 1997;91:291-300.
110. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16:523-30.
111. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-5.
112. Behl C, Widmann M, Trapp T, Holsboer F. 17-β estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995;216:473-82.
113. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and cortisone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 1996; 66:869-72.
114. Chadman K, Joseph JA, Shukitt-Hale B, Prior R, Taglialatela G, Bickford PC. Diets high in antioxidant activity prevent the deleterious effects of oxidative stress on signal transduction and nerve growth factor (NGF). Soc Neurosci 1997;23:348.
115. Gale CR, Martyn CN. Cooper C. Cognitive impairment and mortality in a cohort of elderly people. BMJ 1996;312:608-11.
116. Gilman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA 1995;273:1113-7.
117. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. Aging renders the brain vulnerable to amyloid β-protein toxicity. Nat Med 1998;4:827-31.